Assessment of the Mechanism of Action of Venetoclax (ABT-199) in combination with Ibrutinib (PCI-32765) in relapsed/refractory Chronic Lymphocytic Leukaemia (CLARITY)

Brock, Kristian (Co-Investigator)
Siddique, Shamyla (Principal Investigator)

Cancer Research UK Clinical Trials Unit

Short title	Assessment of the Mechanism of Action of Venetoclax (ABT-199) in combination with Ibrutinib (PCI-32765) in relapsed/refractory Chronic Lymphocytic Leukaemia (CLARITY)
Status	Active
Effective start/end date	1/01/16 → 31/12/26

Funding

BLOODWISE
Janssen-Cilag Limited
Abbvie Ltd

2 Article

A Crossover Randomized Controlled Trial of Priming Interventions to Increase Hand Hygiene at Ward Entrances
Schmidtke, K. A., Aujla, N., Marshall, T., Hussain, A., Hodgkinson, G. P., Arheart, K. L., Birnbach, D. J., Kudrna, L. & Vlaev, I., 17 Jan 2022, In: Frontiers in public health. 9, 11 p., 781359.
Research output: Contribution to journal › Article › peer-review

Open Access
File
66 Downloads (Pure)
Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study
Hillmen, P., Rawstron, A. C., Brock, K., Munoz Vicente, S., Yates, F., Bishop, R., Boucher, B., McDonald, D., Fegan, C., McCaig, A., Schuh, A., Pettitt, A., Gribben, J., Patten, P., Devereux, S., Bloor, A., Fox, C., Forconi, F. & Munir, T., 20 Oct 2019, In: Journal of Clinical Oncology . 37, 30, p. 2722-2729 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
71 Citations (Scopus)

394 Downloads (Pure)